Dose: 0.2 to 1.5 mg/kg
Single Dose: 0.85 (0.85)
Frequency: As recommended.
Route:
Instructions:

. It is of Synthetic origin and belongs to Corticosteroid. . The Molecular Weight of Deflazacort is 441.50.

Deflazacort is contraindicated in conditions like Mild or moderate typhoid due to multiple antibacterial-resistant organisms,Tuberculosis resistant to first line drugs.

The severe or irreversible adverse effects of Deflazacort, which give rise to further complications include Thromboembolism.The symptomatic adverse reactions produced by Deflazacort are more or less tolerable and if they become severe, they can be treated symptomatically, these include Nausea, Insomnia, Dyspepsia, Malaise, Depression, Weight gain, Candidiasis, Psychosis, Bruising, Acne, Increased appetite, Euphoria, Menstrual irregularity, Amenorrhea, Cushing syndrome, Proximal myopathy, Acute pancreatitis, Esophageal ulceration, GI disturbance, Glaucoma, Skin atrophy, Hiccups, Bruising, Peptic ulcer, Abnormal distension, Oesteoporosis, Psychological dependence, Impaired skin, Skin Atrophy, dyspepsia, Musculoskeletal Endocrine, Ophthalmic and Electrolyte disturbances.

Deflazacort is primarily indicated in conditions like Inflammation, Status epilepticus (unlicensed use).

No data regarding the interactions of Deflazacort was found.

Drug should not be given to Pregnant Mothers.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Store at room temperature, .

Deflazacort should be used with caution in patients with adrenal supression and infection (prolong course of corticosteroid increase susceptibility to infection and severity of infection; clinical presentation of infection may also be atypical); children and adolescents (growth retardation possibly irreversible), elderly (close supervision required perticularly on long-term treatment); frequent monitoring required if history of tuberculosis (or X-ray changes), hypertension, recent myocardial infarction (rupture reported), congestive heart failure, liver failure, renal impairment, diabetes mellitus including family history, osteoporosis (post-menopausal women at special risk), glaucoma (including family history), severe effective disorders (perticularly if history of steroid-induced psychosis), epilepsy, peptic ulcer, hypothyroidism, history of steroid myopathy; pregnancy, pregnancy and breast-feeding.